Stereotaxis Inc (STXS) reports strong recurring revenue growth and FDA approval milestones, despite ongoing financial hurdles ...

Its share price is already up an impressive 125% in the last twelve months. Also pleasing for shareholders was the 50% gain in the last three months. In contrast, the longer term returns are negative, ...